Emerging drugs for acute myocardial infarction

Bibliography

• Boersma E, Mercado N, Poldermans D, Acute myocardial infarction. Lancet 2003;361:847-58
   PubMed Web of Science ®Google Scholar
• Newby LK, Rutsch WR, Califf RM, Time from symptom onset to treatment and outcomes after thrombolytic therapy. GUSTO-1 Investigators. J Am Coll Cardiol 1996;27:1646-55
   PubMed Web of Science ®Google Scholar
• Boersma E, Maas AC, Deckers JW, Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour. Lancet 1996;348:771-5
   PubMed Web of Science ®Google Scholar
• Antman EM, Anbe DT, Armstrong PW, ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of patients with acute myocardial infarction). J Am Coll Cardiol 2004;44:E1-211
   PubMedGoogle Scholar
• Keeley EC, Hillis LD. Primary PCI for myocardial infarction with STsegment elevation. N Engl J Med 2007;356:47-54
   PubMed Web of Science ®Google Scholar
• Weaver WD, Simes RJ, Betriu A, Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review. JAMA 1997;278:2093-8
   PubMed Web of Science ®Google Scholar
• Van de Werf F, Ardissino D, Betriu A. Task force on the management of acute myocardial infarction of the European Society of Cardiology: management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2003;24:28-66
   PubMed Web of Science ®Google Scholar
• Montalescot G, Barragan P, Wittenberg O, Abciximab before direct angioplasty and stenting in myocardial infarction regarding acute and long-term follow-up. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2001;344:1895-903
   PubMed Web of Science ®Google Scholar
• Boersma E, Akkerhuis M, Simoons ML. Primary angioplasty versus thrombolysis for acute myocardial infarction. N Engl J Med 2000;342
   Web of Science ®Google Scholar
• Van de Werf F, Bax J, Betriu A, Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 2008;29(23):2909-45
   PubMed Web of Science ®Google Scholar
• Becker R, Fintel DJ, Green D. Aspirin: biology and clinical use. Antithrombotic Therapy. 4th edition. Caddo, OK: Professional Communications, Inc; 2006. p. 89-114
   Google Scholar
• King SB III, Smith SC Jr, Hirshfeld JW Jr, . 2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Grou to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing on Behalf of the 2005 Writing Committee. Circulation 2008;117(2):261-95
   PubMed Web of Science ®Google Scholar
• De Luca G, Suryapranata H, Stone GW, Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. JAMA 2005;293(14):1759-65
   PubMed Web of Science ®Google Scholar
• Gu YL, Fokkema ML, Kampinga MA, Intracoronary versus intravenous abciximab in ST-segment elevation myocardial infarction: rationale and design of the CICERO trial in patients undergoing primary percutaneous coronary intervention with thrombus aspiration. Trial 2009;10(1):90
   Google Scholar
• Schafer JA, Kjesbo NK, Gleason PP. Critical review of prasugrel for formulary decision makers. J Manag Care Pharm 2009;15(4):335-43
   PubMed Web of Science ®Google Scholar
• Farid NA, Smith RL, Gillespie TA, The disposition of prasugrel, a novel thienopyridine, in humans. Drug Metab Dispos 2007;35:1096-104
   PubMed Web of Science ®Google Scholar
• Lau WC, Waskell LA, Watkins PB, Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation 2003;107:32-7
   PubMed Web of Science ®Google Scholar
• Savi P, Pereillo JM, Uzabiaga MF, Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost 2000;84:891-6
   PubMed Web of Science ®Google Scholar
• Storey RF, Judge HM, Wilcox RG, Inhibition of ADP-induced P-selectin expression and platelet-leukocyte conjugate formation by clopidogrel and the P2Y12 receptor antagonist AR-C69931MX but not aspirin. Thromb Haemost 2002;88:488-94
   PubMed Web of Science ®Google Scholar
• Schirmer SH, van der Laan AM, Böhm M, Hotlines and clinical trial updates presented at the European Society of Cardiology Meeting 2009: data from RE-LY, PLATO, MADIT-CRT, PROTECT, SYNTAX, TRITON and more. Clin Res Cardiol 2009;98(11):691-9
   PubMed Web of Science ®Google Scholar
• Savi P, Labouret C, Delesque N, P2y(12), a new platelet ADP receptor, target of clopidogrel. Biochem Biophys Res Commun 2001;283:379-83
   PubMed Web of Science ®Google Scholar
• Fox KA, Mehta SR, Peters R, Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial. Circulation 2004;110:1202-8
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Cannon CP, Gibson CM, Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005;352:1179-89
   PubMed Web of Science ®Google Scholar
• Chen ZM, Jiang LX, Chen YP, Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005;366:1607-21
   PubMed Web of Science ®Google Scholar
• Verstuyft C, Simon T, Kim RB. Personalized medicine and antiplatelet therapy: ready for prime time? Eur Heart J 2009;30(16):1943-63
   PubMed Web of Science ®Google Scholar
• Wallentin L. P2Y(12) inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use. Eur Heart J 2009;30(16):1964-77
   PubMed Web of Science ®Google Scholar
• Clarke TA, Waskell LA. The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin. Drug Metab Dispos 2003;31:53-9
   PubMed Web of Science ®Google Scholar
• Gilard M, Arnaud B, Le Gal G, Influence of omeprazol on the antiplatelet action of clopidogrel associated to aspirin. J Thromb Haemost 2006;4:2508-9
   PubMed Web of Science ®Google Scholar
• Gilard M, Arnaud B, Cornily JC, Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol 2008;51:256-60
   PubMed Web of Science ®Google Scholar
• Ho PM, Maddox TM, Wang L, Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009;301:937-44
   PubMed Web of Science ®Google Scholar
• Pezalla E, Day D, Pulliadath I. Initial assessment of clinical impact of a drug interaction between clopidogrel and proton pump inhibitors. J Am Coll Cardiol 2008;52:1038-9, author reply 1039
   PubMed Web of Science ®Google Scholar
• Sibbing D, Morath T, Stegherr J, Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb Haemost 2009;101:714-9
   PubMed Web of Science ®Google Scholar
• Juurlink DN, Gomes T, Ko DT, A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 2009;180:713-18
   PubMed Web of Science ®Google Scholar
• Simon T, Verstuyft C, Mary-Krause M, Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009;360:363-75
   PubMed Web of Science ®Google Scholar
• Stanek E. Society of Cardiovascular Angiography and Interventions. SCAI Statement on ‘A National Study of the Effect of Individual Proton Pump Unhibitors on Cardiovascular outcomes in Patients Treated with Clopidogrel Following Coronary Stenting: The Clopidogrel Medco Outcomes Study’. Available from: http://wwwscaiorg/drlt1aspx?PAGE_ID_5870. [Last accessed May 2009]
   Google Scholar
• O'Donoghue ML, Braunwald E, Antman EM, Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet 2009;374(9694):989-97
   PubMed Web of Science ®Google Scholar
• Mega JL, Close SL, Wiviott SD, Cytochrome P450 genetic polymorphisms and the response to prasugrel. Relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation 2009;119:2553-60
   PubMed Web of Science ®Google Scholar
• Lordkipanidzé M, Pharand C, Schampaert E, A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur Heart J 2007;28:1702-8
   PubMed Web of Science ®Google Scholar
• Lordkipanidzé M, Pharand C, Nguyen TA, Comparison of four tests to assess inhibition of platelet function by clopidogrel in stable coronary artery disease patients. Eur Heart J 2008;29:2877-85
   PubMed Web of Science ®Google Scholar
• Marcucci R, Gori AM, Paniccia R Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up. Circulation 2009;119(2):237-42
   PubMed Web of Science ®Google Scholar
• Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:188S-203S
   PubMed Web of Science ®Google Scholar
• Tollefsen DM, Majerus DW, Blank MK. Heparin cofactor II. Purification and properties of a heparindependent inhibitor of thrombin in human plasma. J Biol Chem 1982;257:2162-9
   PubMed Web of Science ®Google Scholar
• Barrow RT, Parker ET, Krishnaswamy S, Lollar P. Inhibition by heparin of the human blood coagulation intrinsic pathway factor X activator. J Biol Chem 1994;269:26796-800
   PubMed Web of Science ®Google Scholar
• Singh PP, Arora R, Singh M, Safety and efficacy of prolonged use of unfractionated heparin after percutaneous coronary intervention. Am J Ther 2009 Sep 15. [Epub ahead of print]
   Google Scholar
• Arepally GM, Ortel TL. Clinical practice. Heparin-induced thrombocytopenia. N Engl J Med 2006;355:809-17
   PubMed Web of Science ®Google Scholar
• Greinacher A, Warkentin TE. Recognition, treatment, and prevention of heparin-induced thrombocytopenia: review and update. Thromb Res 2006;118(2):165-76
   PubMed Web of Science ®Google Scholar
• Singh S, Bahekar A, Molnar J, Adjunctive low molecular weight heparin during fibrinolytic therapy in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized control trials. Clin Cardiol 2009;32(7):358-64
   PubMed Web of Science ®Google Scholar
• Anantharaman R, Heatley M, Weston CFM. Hyperglycaemia in acute coronary syndromes: risk-marker or therapeutic target? Heart 2009;95(9):697-703
   PubMed Web of Science ®Google Scholar
• Capes SE, Hunt D, Malmberg K, Gerstein HC. Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview. Lancet 2000;355:773-8
   PubMed Web of Science ®Google Scholar
• Deedwania P, Kosiborod M, Barrett E, American Heart Association Diabetes Committee of the Council on Nutrition, Physical Activity, and Metabolism. Hyperglycemia and acute coronary syndrome: a scientific statement from the American Heart Association Diabetes Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation 2008;117(12):1610-9
   PubMed Web of Science ®Google Scholar
• Opie LH. Metabolic management of acute myocardial infarction comes to the fore and extends beyond control of hyperglycemia. Circulation 2008;117(17):2172-7
   PubMed Web of Science ®Google Scholar
• Kosiborod M, Inzucchi SE, Krumholz HM, Glucose normalization and outcomes in patients with acute myocardial infarction. Arch Intern Med 2009;169(5):438-46
   PubMed Web of Science ®Google Scholar
• Kosiborod M, Inzucchi SE, Goyal A, Relationship between spontaneous and iatrogenic hypoglycemia and mortality in patients hospitalized with acute myocardial infarctio. JAMA 2009;301(15):1556-64
   PubMed Web of Science ®Google Scholar
• Sugidachi A, Asai F, Ogawa T, The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties. Br J Pharmacol 2000;129:1439-46
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Braunwald E, McCabe CH, Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-15
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Trenk D, Frelinger AL, ; PRINCIPLE-TIMI 44 Investigators. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the prasugrel in comparison to clopidogrel for inhibition of platelet activation and aggregation-thrombolysis in myocardial infarction 44 trial. Circulation 2007;116(25):2923-32
   PubMed Web of Science ®Google Scholar
• Montalescot G, Wiviott SD, Braunwald E, ; TRITON-TIMI 38 investigators. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet 2009;373(9665):723-31
   PubMed Web of Science ®Google Scholar
• Serebruany VL. Aggressive chronic platelet inhibition with prasugrel and increased cancer risks: revising oral antiplatelet regimens? Fundam Clin Pharmacol 2009;23(4):411-7
   PubMed Web of Science ®Google Scholar
• Serebruany VL. Platelet inhibition with prasugrel and increased cancer risks: potential causes and implications. Am J Med 2009;122:407-8
   PubMed Web of Science ®Google Scholar
• Meadows TA, Bhatt DL. Clinical aspects of platelet inhibitors and thrombus formation. Circ Res 2007;100:1261-75
   PubMed Web of Science ®Google Scholar
• Ingall AH, Dixon J, Bailey A, Antagonists of the platelet P2T receptor: a novel approach to antithrombotic therapy. J Med Chem 1999;42:213-20
   PubMed Web of Science ®Google Scholar
• Wang K, Zhou X, Zhou Z, Blockade of the platelet P2Y12 receptor by AR-C69931MX sustains coronary artery recanalization and improves the myocardial tissue perfusion in a canine thrombosis model. Arterioscler Thromb Vasc Biol 2003;23:357-62
   PubMed Web of Science ®Google Scholar
• Storey RF, Judge HM, Wilcox RG, Heptinstall S. Inhibition of ADPinduced P-selectin expression and platelet-leukocyte conjugate formation by clopidogrel and the P2Y12 receptor antagonist AR-C69931MX but not aspirin. Thromb Haemost 2002;88:488-94
   PubMed Web of Science ®Google Scholar
• Storey RF, Sanderson HM, White AE, The central role of the P(2T) receptor in amplification of human platelet activation, aggregation, secretion and procoagulant activity. Br J Haematol 2000;110:925-34
   PubMed Web of Science ®Google Scholar
• Greenbaum AB, Ohman EM, Gibson CM, Preliminary experience with intravenous P2Y12 platelet receptor inhibition as an adjunct to reduced-dose alteplase during acute myocardial infarction: results of the Safety, Tolerability and Effect on Patency in Acute Myocardial Infarction (STEP-AMI) angiographic trial. Am Heart J 2007;154(4):702-9
   PubMed Web of Science ®Google Scholar
• Wallentin L, Becker RC, Budaj A, ; PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndrome. N Engl J Med 2009;361(11):1045-57
   PubMed Web of Science ®Google Scholar
• Schlomig A. Ticagrelor–is there need for a new player in the antiplatelet-therapy field? N Engl J Med 2009;361(11):1108-11
   PubMed Web of Science ®Google Scholar
• Gibson CM, Ten Y, Murphy SA, Association of prerandomization anticoagulant switching with bleeding in the setting of percutaneous coronary intervention (A REPLACE-2 analysis). Am J Cardiol 2007;99(12):1687-90
   PubMed Web of Science ®Google Scholar
• Califf RM. Fondaparinux in ST-segment elevation myocardial infarction: the drug, the strategy, the environment, or all of the above? JAMA 2006;295:1579-80
   PubMed Web of Science ®Google Scholar
• Cohen M, Bhatt DL, Alexander JH, Randomized, double-blind, doseranging study of otamixaban, a novel, parenteral, short-acting direct factor Xa inhibitor, in percutaneous coronary intervention: the SEPIA-PCI trial. Circulation 2007;115:2642-51
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Antman EM, Widimsky P, Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trial. Lancet 2009;374(9692):787-95
   PubMed Web of Science ®Google Scholar
• Gibson CM. Randomized comparison of rivaroxaban, an oral direct factor Xa inhibitor, with placebo in patients with acute coronary syndromes: the ATLAS ACS-TIMI 46 Trial. Oral presentation at the AHA meeting; 2008
   Google Scholar
• Alexander J, Wallentin L. Safety of the factor Xa inhibitor, apixaban, in combination with antiplatelet therapy after acute coronary syndromes: results from the APPRAISE-1 dose guiding trial. Presented at ESC; 2008
   Google Scholar
• Serruys PW, Herrman JP, Simon R, A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. Helvetica Investigators. N Engl J Med 1995;333:757-63
   PubMed Web of Science ®Google Scholar
• Roe MT, Granger CB, Puma JA, Comparison of benefits and complications of hirudin versus heparin for patients with acute coronary syndromes undergoing early percutaneous coronary intervention [abstract 1406]. Am J Cardiol 2001;88:1403-6
   PubMed Web of Science ®Google Scholar
• Smith SC, Feldman TE, Hirshfeld JW, American College ofCardiology/American Heart Association Task Force on Practice Guidelines; American College of Cardiology/American Heart Association/ Society for Cardiovascular Angiography and Interventions Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention: ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention–summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). Circulation 2006;113:156-75
   PubMed Web of Science ®Google Scholar
• Stone GW, Witzenbichler B, Guagliumi G, Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 2008;358:2218-30
   PubMed Web of Science ®Google Scholar
• White HD, Chew DP, Hoekstra JW, Safety and efficacy of switching from either unfractionated heparin or enoxaparin to bivalirudin in patients with non- ST-segment elevation acute coronary syndromes managed with an invasive strategy: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategy) trial. J Am Coll Cardiol 2008;51:1734-41
   PubMed Web of Science ®Google Scholar
• Yeh RW, Baron SJ, Healy JL, Anticoagulation with the direct thrombin inhibitor argatroban in patients presenting with acute coronary syndromes. Catheter Cardiovasc Interv 2009;74(2):359-64
   PubMed Web of Science ®Google Scholar
• Mehran R, Lansky AJ, Witzenbichler B, Bi valirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial. Lancet 2009;374(9696):1149-59
   PubMed Web of Science ®Google Scholar
• Pache J, Kastrati A, Mehilli J, A randomized evaluation of the effects of glucose-insulin-potassium infusion on myocardial salvage in patients with acute myocardial infarction treated with reperfusion therapy. Am Heart J 2004;148(1):e3
   PubMedGoogle Scholar
• Ceremuzynski L, Budaj A, Czepiel A, Low-dose glucose-insulin-potassium is ineffective in acute myocardial infarction: results of a randomized multicenter Pol-GIK trial. Cardiovasc Drugs Ther 1999;13(3):191-200
   PubMed Web of Science ®Google Scholar
• Timmer JR, Svilaas T, Ottervanger JP, Glucose-insulin-potassium infusion in patients with acute myocardial infarction without signs of heart failure: the Glucose-Insulin-Potassium Study (GIPS)-II. JACC 2006;47(8):1730-1
   Web of Science ®Google Scholar
• van der Horst IC, Zijlstra F, van ‘t Hof AW, ; Zwolle Infarct Study Group. Glucose-insulin-potassium infusion inpatients treated with primary angioplasty for acute myocardial infarction: the glucose-insulin-potassium study: a randomized trial. JACC 2003;42(5):784-91
   Web of Science ®Google Scholar
• Mehta SR, Yusuf S, Diaz R, ; CREATE-ECLA Trial Group Investigators. Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: The CREATE-ECLA randomized controlled trial. JAMA 2005;293:437-46
   PubMed Web of Science ®Google Scholar
• Díaz R, Paolasso EA, Piegas LS, Metabolic modulation of acute myocardial infarction. The ECLA (Estudios Cardiológicos Latinoamérica) Collaborative Group. Circulation 1998;98(21):2227-34
   PubMed Web of Science ®Google Scholar
• Malmberg K, Rydén L, Efendic S, Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol 1995;26:57-65
   PubMed Web of Science ®Google Scholar
• Malmberg K, Rydén L, Wedel H, Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J 2005;26:650-61
   PubMed Web of Science ®Google Scholar
• Cheung NW, Wong VW, McLean M. The hyperglycemia: intensive insulin infusion in infarction (HI-5) study: a randomized controlled trial of insulin infusion therapy for myocardial infarction. Diabetes Care 2006;29:765-70
   PubMed Web of Science ®Google Scholar
• Demaison L, Fantini E, Sentex E, Trimetazidine: in vitro influence on heart mitochondrial function. Am J Cardiol 1995;76(6):31B-7B
   PubMed Web of Science ®Google Scholar
• Kantor PF, Lucien A, Kozak R, The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res 2000;86(5):580-8
   PubMed Web of Science ®Google Scholar
• Banach M, Rysz J, Goch A, The role of trimetazidine after acute myocardial infarction. Curr Vasc Pharmacol 2008;6(4):282-91
   PubMed Web of Science ®Google Scholar
• Ovide-Bordeaux S, Bescond-Jacquet A, Grynberg A, Cardiac mitochondrial alterations induced by insulin deficiency and hyperinsulinaemia in rats: targeting membrane homeostasis with trimetazidine. Clin Exp Pharmacol Physiol 2005;32(12):1061-70
   PubMed Web of Science ®Google Scholar
• Williams FM, Tanda K, Kus M, Trimetazidine inhibits neutrophil accumulation after myocardial ischaemia and reperfusion in rabbits. J Cardiovasc Pharmacol 1993;22(6):828-33
   PubMed Web of Science ®Google Scholar
• Noble MI, Belcher PR, Drake-Holland AJ. Limitation of infarct size by trimetazidine in the rabbit. Am J Cardiol 1995;76(6):41B-4B
   PubMed Web of Science ®Google Scholar
• Szwed H, Sadowski Z, Elikowski W, Combination treatment in stable effort angina using trimetazidine and metoprolol: results of a randomized, double-blind, multicentre study (TRIMPOL II). TRIMetazidine in POLand. Eur Heart J 2001;22(24):2267-74
   PubMed Web of Science ®Google Scholar
• Szwed H. Clinical benefits of trimetazidine in patients with recurrent angina. Coron Artery Dis. 2004;15(Suppl 1):S17-21
   PubMed Web of Science ®Google Scholar
• Labrou A, Giannoglou G, Zioutas D, Trimetazidine administration minimizes myocardial damage and improves left ventricular function after percutaneous coronary intervention. Am J Cardiovasc Drugs 2007;7(2):143-50
   PubMed Web of Science ®Google Scholar
• Kuralay F, Altekin E, Yazlar AS, Suppression of angioplasty-related inflammation by pre-procedural treatment with trimetazidine. Tohoku J Exp Med 2006;208(3):203-12
   PubMed Web of Science ®Google Scholar
• Rebrova TY, Lasukova TV, Afanas'ev SA, Cardioprotective effect of trimetazidine during thrombolytic therapy in patients with acute myocardial infarction. Bull Exp Biol Med 2002;134(6):559-61
   PubMed Web of Science ®Google Scholar
• Pudil R, Pidrman V, Krejsek J, The effect of trimetazidine on C-reactive protein, cytokines and adhesion molecules in the course of acute myocardial infarction. Acta Medica 2001;44(4):135-40
   Google Scholar
• Steg PG, Grollier G, Gallay P, A randomized double-blind trial of intravenous trimetazidine as adjunctive therapy to primary angioplasty for acute myocardial infarction. Int J Cardiol 2001;77(2-3):263-73
   PubMed Web of Science ®Google Scholar
• Effect of 48-h intravenous trimetazidine on short- and long-term outcomes of patients with acute myocardial infarction, with and without thrombolytic therapy; A double-blind, placebo-controlled, randomized trial. The EMIP-FR Group. European Myocardial Infarction Project–Free Radicals. Eur Heart J 2000;21(18):1537-46
   PubMed Web of Science ®Google Scholar
• Wilson SR, Scirica BM, Braunwald E, Efficacy of ranolazine in patients with chronic angina observations from the randomized, double-blind, placebo-controlled MERLIN-TIMI (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Segment Elevation Acute Coronary Syndromes) 36 Trial. J Am Coll Cardiol 2009;53(17):1510-6
   PubMed Web of Science ®Google Scholar
• Scirica BM, Morrow DA, Budaj A, Ischemia detected on continuous electrocardiography after acute coronary syndrome: observations from the MERLIN-TIMI 36 (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndrome-Thrombolysis In Myocardial Infarction 36) trial. J Am Coll Cardiol 2009;53(16):1411-21
   PubMed Web of Science ®Google Scholar
• Scirica BM, Morrow DA, Hod H, Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation 2007;116(15):1647-52
   PubMed Web of Science ®Google Scholar
• Allely MC, Alps BJ. Prevention of myocardial enzymerelease by ranolazine in a primate model of ischaemia with reperfusion. Br J Pharmacol 1990;99:5-6
   PubMed Web of Science ®Google Scholar
• Black SC, Gralinski MR, McCormack JG, Effect of ranolazine on infarct size in a canine model of regional myocardial ischemia/reperfusion. J Cardiovasc Pharmacol 1994;24:921-8
   PubMed Web of Science ®Google Scholar
• Hale SL, Shryock JC, Belardinelli L, Late sodium current inhibition as a new cardioprotective approach. J Mol Cell Cardiol 2008;44(6):954-67
   PubMed Web of Science ®Google Scholar
• Zeymer U, Suryapranata H, Monassier JP, The Na(þ)/H(þ) exchange inhibitor eniporide as an adjunct to early reperfusion therapy for acute myocardial infarction. Results of the evaluation of the safety and cardioprotective effects of eniporide in acute myocardial infarction (ESCAMI) trial. J Am Coll Cardiol 2001;38:1644-50
   PubMed Web of Science ®Google Scholar
• Theroux P, Chaitman BR, Danchin N, Inhibition of the sodium-hydrogen exchanger with cariporide to prevent myocardial infarction in high-risk ischemic situations. Main results of the GUARDIAN trial. Guard during ischemia against necrosis (GUARDIAN) Investigators. Circulation 2000;102:3032-8
   PubMed Web of Science ®Google Scholar
• Mentzer RM Jr, Bartels C, Bolli R, Sodium-hydrogen exchange inhibition by cariporide to reduce the risk of ischemic cardiac events in patients undergoing coronary artery bypass grafting: results of the EXPEDITION study. Ann Thorac Surg 2008;85:1261-70
   PubMed Web of Science ®Google Scholar
• Inserte J, Barrabés JA, Hernando V, Garcia-Dorado D. Orphan targets for reperfusion injury. Cardiovasc Res 2009;83(2):169-78
   PubMed Web of Science ®Google Scholar
• Bar FW, Tzivoni D, Dirksen MT, Results of the first clinical study of adjunctive CAldaret (MCC-135) in patients undergoing primary percutaneous coronary intervention for ST-Elevation Myocardial Infarction: the randomized multicentre CASTEMI study. Eur Heart J 2006;27:2516-23
   PubMed Web of Science ®Google Scholar
• Kitakaze M, Asakura M, Kim J, Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomized trials. Lancet 2007;370:1483-93
   PubMed Web of Science ®Google Scholar
• Mahaffey KW, Puma JA, Barbagelata NA, Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction STudy of Adenosine (AMISTAD) trial. J Am Coll Cardiol 1999;34:1711-20
   PubMed Web of Science ®Google Scholar
• Ross AM, Gibbons RJ, Stone GW, A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II). J Am Coll Cardiol 2005;45:1775-80
   PubMed Web of Science ®Google Scholar
• Movahed MR, Butman SM. The pathogenesis and treatment of no-reflow occurring during percutaneous coronary intervention. Cardiovasc Revasc Med 2008;9(1):56-61
   PubMedGoogle Scholar
• Kelly RV, Cohen MG, Stouffer GA. Incidence and management of “noreflow” following percutaneous coronary interventions. Am J Med Sci 2005;329:78-85
   PubMed Web of Science ®Google Scholar
• Resnic FS, Wainstein M, Lee MK, Noreflow is an independent predictor of death and myocardial infarction after percutaneous coronary intervention. Am Heart J 2003;145:42-6
   PubMed Web of Science ®Google Scholar
• Morishima I, Sone T, Okumura K, Angiographic no-reflow phenomenon as a predictor of adverse long-term outcome in patientstreated with percutaneous transluminal coronary angioplasty for first acute myocardial infarction. J Am Coll Cardiol 2000;36:1202-9
   PubMed Web of Science ®Google Scholar
• Lee CH, Wong HB, Tan HC, Impact of reversibility of no reflow phenomenon on 30-day mortality following percutaneous revascularization for acute myocardial infarction—insights from a 1,328 patient registry. J Interv Cardiol 2005;18:261-6
   PubMedGoogle Scholar
• Kaplan BM, Benzuly KH, Kinn JW, Treatment of no-reflow in degenerated saphenous vein graft interventions: comparison of intracoronary verapamil and nitroglycerin. Catheter Cardiovasc Diagn 1996;39:113-8
   PubMedGoogle Scholar
• Klein LW, Kern MJ, Berger P, Society of cardiac angiography and interventions: suggested management of the no-reflow phenomenon in the cardiac catheterization laboratory. Catheter Cardiovasc Interv 2003;60:194-201
   PubMed Web of Science ®Google Scholar
• Piana RN, Paik GY, Moscucci M, Incidence and treatment of ‘noreflow’ after percutaneous coronary intervention. Circulation 1994;89:2514-8
   PubMed Web of Science ®Google Scholar
• Michaels AD, Appleby M, Otten MH, Pretreatment with intragraft verapamil prior to percutaneous coronary intervention of saphenous vein graft lesions: results of the randomized, controlled vasodilator prevention on noreflow (VAPOR) trial. J Invasive Cardiol 2002;14:299-302
   PubMedGoogle Scholar
• Marzilli M, Orsini E, Marraccini P, Testa R. Beneficial effects of intracoronary adenosine as an adjunct to primary angioplasty in acute myocardial infarction. Circulation 2000;101:2154-9
   PubMed Web of Science ®Google Scholar
• Fischell TA, Carter AJ, Foster MT, Reversal of “no reflow” during vein graft stenting using high velocity boluses of intracoronary adenosine. Catheter Cardiovasc Diagn 1998;45:360-5
   PubMedGoogle Scholar
• Dillon WC, Hadian D, Ritchie ME. Refractory no-reflow successfully treated with local infusion of high-dose adenosine and verapamil–a case report. Angiology 2001;52:137-41
   PubMed Web of Science ®Google Scholar
• Pasceri V, Pristipino C, Pelliccia F, Effects of the nitric oxide donor nitroprusside on no-reflow phenomenon during coronary interventions for acute myocardial infarction. Am J Cardiol 2005;95:1358-61
   PubMed Web of Science ®Google Scholar
• Hochman JS, Sleeper LA, Webb JG, Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should we emergently revascularize occluded coronaries for cardiogenic shock. N Engl J Med 1999;341:625-34
   PubMed Web of Science ®Google Scholar
• Valente S, Lazzeri C, Vecchio S, Predictors of in-hospital mortality after percutaneous coronary intervention for cardiogenic shock. Int J Cardiol 2007;114(2):176-82
   PubMed Web of Science ®Google Scholar
• Valente S, Lazzeri C, Chiostri M, Time of onset and outcome of cardiogenic shock in acute coronary syndromes. J Cardiovasc Med (Hagerstown) 2008;9(12):1235-40
   PubMed Web of Science ®Google Scholar
• Hochman JS. Cardiogenic shock complicating acute myocardial infarction: Expanding the paradigm. Circulation 2003;107:2998-3002
   PubMed Web of Science ®Google Scholar
• Hochman JS, Sleeper LA, Webb JG, Early revascularization and long-term survival in cardiogenic shock complicating acute myocardial infarction. J Am Med Assoc 2006;295:2511-5
   PubMed Web of Science ®Google Scholar
• Ruiz-Bailén M, Rucabado-Aguilar L, Expósito-Ruiz M, Cardiogenic shock in acute coronary syndrome. Med Sci Monit 2009;15(3):RA57-66
   PubMed Web of Science ®Google Scholar
• den Uil CA, Lagrand WK, Valk SD, Management of cardiogenic shock: focus on tissue perfusion. Curr Probl Cardiol 2009;34(8):330-49
   PubMed Web of Science ®Google Scholar
• Cheng JM, Valk SD, den Uil CA, Usefulness of intra-aortic balloon pump counterpulsation in patients with cardiogenic shock from acute myocardial infarction. Am J Cardiol 2009;104(3):327-32
   PubMed Web of Science ®Google Scholar
• Prondzinsky R, Lemm H, Swyter M, Intra-aortic balloon counterpulsation in patients with acute myocardial infarction complicated by cardiogenic shock: the prospective, randomized IABP SHOCK Trial for attenuation of multiorgan dysfunction syndrome. Crit Care Med 2009. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Dickstein K, Cohen-Solal A, Filippatos GS, ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. Eur Heart J 2008;29:2388-442
   PubMed Web of Science ®Google Scholar
• Follath F, Cleland JG, Just H, Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 2002;360:196-202
   PubMed Web of Science ®Google Scholar
• Russ MA, Prondzinsky R, Christoph A, Hemodynamic improvement following levosimendan treatment in patients with acute myocardial infarction and cardiogenic shock. Crit Care Med 2007;35:2732-9
   PubMed Web of Science ®Google Scholar
• Mebazaa A, Nieminen MS, Packer M, Levosimendan vs dobutamine for patients with acute decompensated heart failure: The SURVIVE randomized trial. J Am Med Assoc 2007;297:1883-91
   PubMed Web of Science ®Google Scholar
• Fuhrmann JT, Schmeisser A, Schulze MR, Levosimendan is superior to enoximone in refractory cardiogenic shock complicating acute myocardial infarction. Crit Care Med 2008;36:2257-66
   PubMed Web of Science ®Google Scholar
• Tsai FC, Marelli D, Laks H, Short-term bridge to heart transplant using the BVS 5000 external ventricular assist device. Am J Transplant 2002;2:646-51
   PubMed Web of Science ®Google Scholar
• Idelchik GM, Simpson L, Civitello AB, Use of the percutaneous left ventricular assist device in patients with severe refractory cardiogenic shock as a bridge to long-term left ventricular assist device implantation. J Heart LungTransplant 2008;27:106-11
   PubMed Web of Science ®Google Scholar
• Burkhoff D, Cohen H, Brunckhorst C, A randomized multicenter clinical study to evaluate the safety and efficacy of the TandemHeart percutaneous ventricular assist device versus conventional therapy with intraaortic balloon pumping for treatment of cardiogenic shock. Am Heart J 2006;152(469):e1-8
   PubMedGoogle Scholar
• Thiele H, Sick P, Boudriot E, Randomized comparison of intra-aortic balloon support with a percutaneous left ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock. Eur Heart J 2005;26:1276-83
   PubMed Web of Science ®Google Scholar
• Sjauw KD, Engström AE, Vis MMKD, A systematic review and meta-analysis of intra-aortic balloon pump therapy in ST-elevation myocardial infarction: should we change the guidelines? Eur Heart J 2009;30(4):459-68
   PubMed Web of Science ®Google Scholar
• Myerburg RJ, Reddy V, Castellanos A. Indications for implantable cardioverter-defibrillators based on evidence and judgment. J Am Coll Cardiol 2009;54(9):747-63
   PubMed Web of Science ®Google Scholar
• Zipes DP, Camm AJ, Borggrefe M, ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death–executive summary: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiolog y Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Eur Heart J 2006;27:2099-140
   PubMed Web of Science ®Google Scholar
• Sarter BH, Finkle JK, Gerszten RE, Buxton AE. What is the risk of sudden cardiac death in patients presenting with hemodynamically stable sustained ventricular tachycardia after myocardial infarction? J Am Coll Cardiol 1996;28:122-9
   PubMed Web of Science ®Google Scholar
• Singh S, Arora R, Handa K, Stem cells improve left ventricular function in acute myocardial infarction. Clin Cardiol 2009;32(4):176-80
   PubMed Web of Science ®Google Scholar